1. Home
  2. VRCA vs DHIL Comparison

VRCA vs DHIL Comparison

Compare VRCA & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRCA
  • DHIL
  • Stock Information
  • Founded
  • VRCA 2013
  • DHIL 1990
  • Country
  • VRCA United States
  • DHIL United States
  • Employees
  • VRCA N/A
  • DHIL N/A
  • Industry
  • VRCA Biotechnology: Pharmaceutical Preparations
  • DHIL Investment Managers
  • Sector
  • VRCA Health Care
  • DHIL Finance
  • Exchange
  • VRCA Nasdaq
  • DHIL Nasdaq
  • Market Cap
  • VRCA 363.1M
  • DHIL 430.4M
  • IPO Year
  • VRCA 2018
  • DHIL 1995
  • Fundamental
  • Price
  • VRCA $0.69
  • DHIL $150.15
  • Analyst Decision
  • VRCA Hold
  • DHIL
  • Analyst Count
  • VRCA 5
  • DHIL 0
  • Target Price
  • VRCA $6.00
  • DHIL N/A
  • AVG Volume (30 Days)
  • VRCA 749.9K
  • DHIL 17.7K
  • Earning Date
  • VRCA 11-04-2024
  • DHIL 11-04-2024
  • Dividend Yield
  • VRCA N/A
  • DHIL 4.00%
  • EPS Growth
  • VRCA N/A
  • DHIL 21.33
  • EPS
  • VRCA N/A
  • DHIL 17.67
  • Revenue
  • VRCA $9,210,000.00
  • DHIL $145,795,446.00
  • Revenue This Year
  • VRCA $54.16
  • DHIL N/A
  • Revenue Next Year
  • VRCA $99.78
  • DHIL N/A
  • P/E Ratio
  • VRCA N/A
  • DHIL $8.50
  • Revenue Growth
  • VRCA 187.45
  • DHIL 5.76
  • 52 Week Low
  • VRCA $0.61
  • DHIL $135.44
  • 52 Week High
  • VRCA $11.41
  • DHIL $173.25
  • Technical
  • Relative Strength Index (RSI)
  • VRCA 33.00
  • DHIL 25.46
  • Support Level
  • VRCA $0.61
  • DHIL $158.02
  • Resistance Level
  • VRCA $1.32
  • DHIL $160.95
  • Average True Range (ATR)
  • VRCA 0.11
  • DHIL 3.01
  • MACD
  • VRCA -0.02
  • DHIL -1.83
  • Stochastic Oscillator
  • VRCA 12.08
  • DHIL 5.65

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

About DHIL Diamond Hill Investment Group Inc.

Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.

Share on Social Networks: